Filtered By:
Condition: Hypertension
Nutrition: Herbs
This page shows you your search results in order of relevance. This is page number 6.
Order by Relevance | Date
Total 92 results found since Jan 2013.
Revealing new therapeutic opportunities in hypertension through network-driven integrative genetic analysis and drug target prediction approach
Gene. 2021 Jul 19;801:145856. doi: 10.1016/j.gene.2021.145856. Online ahead of print.ABSTRACTEpidemiological studies have established that untreated hypertension (HTN) is a major independent risk factor for developing cardiovascular diseases (CVD), stroke, renal failure, and other conditions. Several important studies have been published to prevent and manage HTN; however, antihypertensive agents' optimal choice remains controversial. Therefore, the present study is undertaken to update our knowledge in the primary treatment of HTN, specifically in the setting of other three important diseases. MicroRNAs (miRNAs) are remar...
Source: Gene - July 22, 2021 Category: Genetics & Stem Cells Authors: Kavita Sharma Prithvi Singh Md Amjad Beg Ravins Dohare Fareeda Athar Mansoor Ali Syed Source Type: research
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Withania somnifera (L.) Dunal (Ashwagandha): A comprehensive review on ethnopharmacology, pharmacotherapeutics, biomedicinal and toxicological aspects
Biomed Pharmacother. 2021 Nov;143:112175. doi: 10.1016/j.biopha.2021.112175. Epub 2021 Sep 27.ABSTRACTWithania somnifera (L.) Dunal (Solanaceae) has been used as a traditional Rasayana herb for a long time. Traditional uses of this plant indicate its ameliorative properties against a plethora of human medical conditions, viz. hypertension, stress, diabetes, asthma, cancer etc. This review presents a comprehensive summary of the geographical distribution, traditional use, phytochemistry, and pharmacological activities of W. somnifera and its active constituents. In addition, it presents a detailed account of its presence as...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 15, 2021 Category: Drugs & Pharmacology Authors: Subhabrata Paul Shreya Chakraborty Uttpal Anand Swarnali Dey Samapika Nandy Mimosa Ghorai Suchismita Chatterjee Saha Manoj Tukaram Patil Ramesh Kandimalla Jaros ław Proćków Abhijit Dey Source Type: research
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Medicinal Plants in the Treatment of Hypertension: A Review
Adv Pharm Bull. 2021 Sep;11(4):601-617. doi: 10.34172/apb.2021.090. Epub 2020 Nov 1.ABSTRACTTraditional medicine is a comprehensive term for ancient, culture-bound health care practices that existed before the use of science in health matters and has been used for centuries. Medicinal plants are used to treat patients with cardiovascular diseases, which may occur due to ailments of the heart and blood vessels and comprise heart attacks, cerebrovascular diseases, hypertension, and heart failure. Hypertension causes difficulty in the functioning of the heart and is involved in atherosclerosis, raising the risk of heart attac...
Source: Atherosclerosis - December 10, 2021 Category: Cardiology Authors: Raha Kamyab Hossein Namdar Mohammadali Torbati Morteza Ghojazadeh Mostafa Araj-Khodaei Seyyed Mohammad Bagher Fazljou Source Type: research
Anti-Diabesity Middle Eastern Medicinal Plants and Their Action Mechanisms
Evid Based Complement Alternat Med. 2022 Jul 18;2022:2276094. doi: 10.1155/2022/2276094. eCollection 2022.ABSTRACTOver the last four decades, the escalation in diabetes and obesity rates has become epidemic all over the world. Diabesity describes the strong link between T2D and obesity. It correlates deeper with the elevated risks of developing cardiovascular disease hypertension, stroke, and several malignancies. Therapeutic usage of medicinal plants and natural products in the treatment of diabetes and obesity has long been known to physicians of Greco-Arab and Islamic medicine. Improved versions of their abundant medici...
Source: Evidence-based Complementary and Alternative Medicine - July 28, 2022 Category: Complementary Medicine Authors: Bashar Saad Abdalsalam Kmail Sameena Z H Haq Source Type: research
Current Landscape of Therapeutics for the Management of Hypertension - A Review
Curr Drug Deliv. 2023 Jun 23. doi: 10.2174/1567201820666230623121433. Online ahead of print.ABSTRACTHypertension is a critical health problem. It is also the primary cause of coronary heart disease, stroke, and renal vascular disease. The use of herbal drugs in the management of any disease is increasing. They are considered the best immune booster to fight against several types of diseases. To date, the demand for herbal drugs has been increasing because of their excellent properties. This review highlights antihypertensive drugs, polyphenols, and synbiotics for managing hypertension. Evidence is mounting in favour of mor...
Source: Current Drug Delivery - June 26, 2023 Category: Drugs & Pharmacology Authors: Neda Fatima Sumel Ashique Aakash Upadhyay Shubneesh Kumar Himanshu Kumar Nitish Kumar Prashant Kumar Source Type: research
